ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon PrintIcon Twitter
Pharmaceuticals

Japanese stem cell treatment for Parkinson's set for US trials

Sumitomo Dainippon Pharma aims for commercial breakthrough in iPS therapies

Work is underway to use iPS cells -- cells reprogrammed to an embryonic state -- in regenerative treatments for incurable diseases.

OSAKA -- A Japanese drugmaker plans clinical trials in the U.S. of a regenerative treatment for Parkinson's disease that uses reprogrammed cells, Nikkei has learned.

Sponsored Content

About Sponsored Content This content was commissioned by Nikkei's Global Business Bureau.

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more